Compugen (CGEN) has released an update.
Compugen Ltd. has announced promising data on the anti-tumor activity and safety of its triple combination therapy involving COM701, COM902, and pembrolizumab in patients with platinum-resistant ovarian cancer. These findings, presented at the Society for Immunotherapy of Cancer Annual Meeting, highlight the potential of COM701 as a differentiated immune checkpoint inhibitor, offering hope for improved treatment options. The company’s confidence in advancing COM701 is bolstered by consistent data from multiple studies, suggesting a unique mechanism of action that may enhance progression-free survival in ovarian cancer patients.
For further insights into CGEN stock, check out TipRanks’ Stock Analysis page.
Trending Articles
- Super Micro Computer (SMCI) Says Special Committee Found No Evidence of Fraud
- Netflix’s France and Netherlands Offices Raided for Possible Tax Fraud
- Class Action Lawsuit Against Bumble Inc. (NASDAQ:BMBL)
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
